

Revised 30 Mar. 2015 rm (Vers. 1.1)



USA: RUO

This kit is intended for Research Use Only.

Not intended for diagnostic purposes.

Product Patent Protected: Pat. US 7,320,894B2; US 7,411,048 B2, US 7,649,081 B2, US 7,749,713 B2, US 7,998,691 B2, US 8,003,338 B2, US 8,017,737 B2, US 8,263,352 B2, US 8,304,197 B2, US 8,304,258 B2, EU 2 109 624, EU 603 43 464.9, EU 1,578,254, Japan 4638350, Russia 2 359 268 C2, China 200380108964.8, Hong Kong 1114419, Canada 2,506,668. EU 07 723 512.5 (Pending)

1 INTRODUCTION

1.1 Intended Use

The **DRG Hepcidin 25 (bioactive) HS ELISA** is a **high sensitive** enzyme immunoassay for measurement of Hepcidin-25 in serum and plasma.

2 PRINCIPLE OF THE TEST

The DRG Hepcidin 25 (bioactive) HS ELISA Kit is a solid phase enzyme-linked immunosorbent assay (ELISA) based on the principle of competitive binding.

The microtiter wells are coated with a monoclonal (mouse) antibody directed towards an antigenic site of the Hepcidin-25 molecule. Endogenous Hepcidin-25 of a sample competes with a Hepcidin-25-biotin conjugate (Enzyme Conjugate) for binding to the coated antibody.

After incubation the microtiter plate is washed to stop the competition reaction. In the following incubation the bound biotin molecules are detected with streptavidin peroxidase (Enzyme Complex).

After incubation the plate is washed the second time.

After addition of the substrate solution, the intensity of color developed is inversely proportional to the concentration of Hepcidin-25 in the sample.

3 WARNINGS AND PRECAUTIONS

- 1. This kit is for research use only. For professional use only.
- 2. All reagents of this test kit which contain human serum or plasma have been tested and confirmed negative for HIV I/II, HBsAg and HCV by FDA approved procedures. All reagents, however, should be treated as potential biohazards in use and for disposal.
- 3. Before starting the assay, read the instructions completely and carefully. <u>Use the valid version of instructions for use provided with the kit.</u> Be sure that everything is understood.
- 4. The microplate contains snap-off strips. Unused wells must be stored at 2 to 8 °C in the sealed foil pouch and used in the frame provided.
- 5. Pipetting of samples and reagents must be done as quickly as possible and in the same sequence for each step.

DRG



DRG[®] Hepcidin 25 (bioactive) HS ELISA (EIA-5782)

((

Revised 30 Mar. 2015 rm (Vers. 1.1)

- 6. Use reservoirs only for single reagents. This especially applies to the substrate reservoirs. Using a reservoir for dispensing a substrate solution that had previously been used for the conjugate solution may turn solution colored. Do not pour reagents back into vials as reagent contamination may occur.
- 7. Mix the contents of the microplate wells thoroughly to ensure good test results. Do not reuse microwells.
- 8. Do not let wells dry during assay; add reagents immediately after completing the rinsing steps.
- 9. Allow the reagents to reach room temperature (21-26°C) before starting the test. Temperature will affect the absorbance readings of the assay. However, values for the samples will not be affected.
- 10. Never pipet by mouth and avoid contact of reagents and specimens with skin and mucous membranes.
- 11. Do not smoke, eat, drink or apply cosmetics in areas where specimens or kit reagents are handled.
- 12. Wear disposable latex gloves when handling specimens and reagents. Microbial contamination of reagents or specimens may give false results.
- 13. Handling should be done in accordance with the procedures defined by an appropriate national biohazard safety guideline or regulation.
- 14. Do not use reagents beyond expiry date as shown on the kit labels.
- 15. All indicated volumes have to be performed according to the protocol. Optimal test results are only obtained when using calibrated pipettes and microtiterplate readers.
- 16. Do not mix or use components from kits with different lot numbers. It is advised not to exchange wells of different plates even of the same lot. The kits may have been shipped or stored under different conditions and the binding characteristics of the plates may result slightly different.
- 17. Avoid contact with Stop Solution containing 0.5 M H₂SO₄. It may cause skin irritation and burns.
- 18. Some reagents contain Proclin 300, BND and/or MIT as preservatives. In case of contact with eyes or skin, flush immediately with water.
- 19. TMB substrate has an irritant effect on skin and mucosa. In case of possible contact, wash eyes with an abundant volume of water and skin with soap and abundant water. Wash contaminated objects before reusing them. If inhaled, take the person to open air.
- 20. Chemicals and prepared or used reagents have to be treated as hazardous waste according to the national biohazard safety guideline or regulation.
- 21. For information on hazardous substances included in the kit please refer to Safety Data Sheets. Safety Data Sheets for this product are available upon request directly from DRG.







Revised 30 Mar. 2015 rm (Vers. 1.1)

4 REAGENTS

- 4.1 Reagents provided
- 1. *Microtiterwells*, 12 x 8 (break apart) strips, 96 wells; Wells coated with anti-Hepcidin-25 antibody (monoclonal).
- Zero Standard, 1 vial, 3 mL, ready to use; 0 ng/mL Contains non-mercury preservative.
- Standard (Standard 1 5), 5 vials, 0.5 mL, ready to use; Concentrations: 1 - 3 - 9 - 27 - 81 ng/mL Conversion: 1 ng/mL = 0.358 nmol/L Contain non-mercury preservative.
- 4. *Control Low & High*, 2 vials, 0.5 mL each, ready to use; For control values and ranges please refer to vial label or QC-Datasheet. Contain non-mercury preservative.
- 5. *Enzyme Conjugate*, 1 vial, 7 mL, ready to use, Hepcidin-25 conjugated to biotin; Contains non-mercury preservative.
- 6. *Enzyme Complex*, 1 vial, 14 mL, ready to use, Strepavidin conjugated to horseradish peroxidase Contains non-mercury preservative.
- 7. *Substrate Solution*, 1 vial, 14 mL, ready to use, Tetramethylbenzidine (TMB).
- Stop Solution, 1 vial, 14 mL, ready to use, contains 0.5 M H₂SO₄, Avoid contact with the stop solution. It may cause skin irritations and burns.
- 9. *Wash Solution*, 1 vial, 30 mL (40X concentrated), See "Reagent Preparation".

Note: Additional Zero Standard for sample dilution is available upon request.







(€

Revised 30 Mar. 2015 rm (Vers. 1.1)

4.2 Materials required but not provided

- A microtiter plate calibrated reader $(450 \pm 10 \text{ nm})$ (e.g. the DRG Instruments Microtiter Plate Reader)
- Calibrated variable precision micropipettes
- Absorbent paper
- Distilled or deionized water
- Timer
- Semi logarithmic graph paper or software for data reduction

4.3 Storage Conditions

When stored at 2 to 8 °C unopened reagents will retain reactivity until expiration date. Do not use reagents beyond this date.

Opened reagents must be stored at 2 to 8 °C. Microtiter wells must be stored at 2 to 8 °C. Once the foil bag has been opened, care should be taken to close it tightly again.

Opened kits retain activity for two months if stored as described above.

4.4 Reagent Preparation

Bring all reagents and required number of strips to room temperature prior to use.

Wash Solution

Add deionized water to the 40X concentrated Wash Solution.

Dilute 30 mL of concentrated *Wash Solution* with 1170 mL deionized water to a final volume of 1200 mL. *The diluted Wash Solution is stable for 2 weeks at room temperature.*

4.5 Disposal of the Kit

The disposal of the kit must be made according to the national regulations. Special information for this product is given in the Material Safety Data Sheet.

4.6 Damaged Test Kits

In case of any severe damage to the test kit or components, DRG has to be informed in writing, at the latest, one week after receiving the kit. Severely damaged single components should not be used for a test run. They have to be stored until a final solution has been found. After this, they should be disposed according to the official regulations.









5 SPECIMEN COLLECTION AND PREPARATION

Serum or plasma (EDTA-, heparin- or citrate plasma) can be used in this assay.

Do not use hemolytic, icteric or lipemic specimens. Please note: Samples containing sodium azide should not be used in the assay.

5.1 **Specimen Collection**

Serum:

Collect blood by venipuncture (e.g. Sarstedt Monovette for serum), allow to clot, and separate serum by centrifugation at room temperature. Do not centrifuge before complete clotting has occurred. Samples containing anticoagulant may require increased clotting time.

Plasma:

Whole blood should be collected into centrifuge tubes containing anti-coagulant (e.g. Sarstedt Monovette with the appropriate plasma preparation) and centrifuged immediately after collection.

5.2 **Specimen Storage and Preparation**

Specimens should be capped and may be stored for up to 4 days at 2 to 8 °C prior to assaying. Specimens held for a longer time (up to 12 months) should be frozen only once at -20 °C prior to assay. Thaved samples should be inverted several times prior to testing.

5.3 **Specimen Dilution**

If in an initial assay, a specimen is found to contain more than the highest standard, the specimens can be diluted with Zero Standard and reassayed as described in Assay Procedure.

For the calculation of the concentrations this dilution factor has to be taken into account. Example:

a) dilution 1:10: $10 \,\mu\text{L} \text{ sample} + 90 \,\mu\text{L} Zero Standard (mix thoroughly)$ 10 µL dilution a) 1:10 + 90 µL Zero Standard (mix thoroughly). b) dilution 1:100:

ASSAY PROCEDURE 6

General Remarks 6.1

- All reagents and specimens must be allowed to come to room temperature before use. All reagents must be mixed without foaming.
- Once the test has been started, all steps should be completed without interruption.
- Use new disposal plastic pipette tips for each standard, control or sample in order to avoid cross contamination.



USA: RUO







Revised 30 Mar. 2015 rm (Vers. 1.1)

- Absorbance is a function of the incubation time and temperature. Before starting the assay, it is recommended that all reagents are ready, caps removed, all needed wells secured in holder, etc. This will ensure equal elapsed time for each pipetting step without interruption.
- As a general rule the enzymatic reaction is linearly proportional to time and temperature.

6.2 Test Procedure

Each run must include a standard curve.

- 1. Secure the desired number of Microtiter wells in the frame holder.
- 2. Dispense 20 µL of each *Standard, Control* and samples with new disposable tips into appropriate wells.
- 3. Dispense **50 μL** *Enzyme Conjugate* into each well. Thoroughly mix for 10 seconds. It is important to have a complete mixing in this step.
- 4. Incubate for **60 minutes** at room temperature.
- 5. Briskly shake out the contents of the wells. Rinse the wells.
 4 x with 400 µL diluted Wash Solution per well (if a plate washer is used) or
 4 x with 300 µL diluted Wash Solution per well for manual washing. Strike the wells sharply on absorbent paper to remove residual droplets. Important note:

The sensitivity and precision of this assay is markedly influenced by the correct performance of the washing procedure!

- 6. Dispense 100 µL of *Enzyme Complex* into appropriate wells.
- 7. Incubate for **30 minutes** at room temperature.
- Briskly shake out the contents of the wells. Rinse the wells.
 4 x with 400 μL diluted *Wash Solution* per well (if a plate washer is used) or
 4 x with 300 μL diluted *Wash Solution* per well for manual washing.
 Strike the wells sharply on absorbent paper to remove residual droplets.
- 9. Add **100 µL** of *Substrate Solution* to each well.
- 10. Incubate for **20 minutes** at room temperature.
- 11. Stop the enzymatic reaction by adding 100 µL of Stop Solution to each well.
- 12. Determine the absorbance (OD) of each well at 450 ± 10 nm with a microtiter plate reader. It is recommended that the wells be read within 10 minutes after adding the *Stop Solution*.







Revised 30 Mar. 2015 rm (Vers. 1.1)

6.3 Calculation of Results

- 1. Calculate the average absorbance values for each set of standards, controls and samples.
- 2. Using semi-logarithmic graph paper, construct a standard curve by plotting the mean absorbance obtained from each standard against its concentration with absorbance value on the vertical (Y) axis and concentration on the horizontal (X) axis.
- 3. Using the mean absorbance value for each sample determine the corresponding concentration from the standard curve.
- 4. Automated method: The results in the Instructions for Use have been calculated automatically using a 4-Parameter curve fit. (4 Parameter Rodbard or 4 Parameter Marquardt are the preferred methods.) Other data reduction functions may give slightly different results.
- 5. The concentration of the samples can be read directly from this standard curve. Samples with concentrations higher than that of the highest standard have to be further diluted or reported as > 81 ng/mL. For the calculation of the concentrations this dilution factor has to be taken into account.

6.3.1 Example of Typical Standard Curve

The following data is for demonstration only and **cannot** be used in place of data generations at the time of assay.

Standard	Optical Units (450 nm)
Standard 0 (0 ng/mL)	2.03
Standard 1 (1 ng/mL)	1.70
Standard 2 (3 ng/mL)	1.29
Standard 3 (9 ng/mL)	0.77
Standard 4 (27 ng/mL)	0.37
Standard 5 (81 ng/mL)	0.17

7 EXPECTED NORMAL VALUES

It is strongly recommended that each laboratory should determine its own normal and abnormal values.

8 QUALITY CONTROL

Good laboratory practice requires that controls be run with each calibration curve. A statistically significant number of controls should be assayed to establish mean values and acceptable ranges to assure proper performance.

It is recommended to use control samples according to state and federal regulations. The use of control samples is advised to assure the day to day validity of results. Use controls at both normal and pathological levels.

The controls and the corresponding results of the QC-Laboratory are stated in the QC certificate added to the kit. The values and ranges stated on the QC sheet always refer to the current kit lot and should be used for direct comparison of the results.

DRG International Inc., USA	1	Page 7 of 11 Pages
Fax: (973) 564-7556 • E-mail: <u>corp@drg-international.com</u> •	• \	Web: <u>www.drg-international.com</u>







Revised 30 Mar. 2015 rm (Vers. 1.1)

Employ appropriate statistical methods for analyzing control values and trends. If the results of the assay do not fit to the established acceptable ranges of control materials results should be considered invalid.

In this case, please check the following technical areas: Pipetting and timing devices; photometer, expiration dates of reagents, storage and incubation conditions, aspiration and washing methods.

After checking the above mentioned items without finding any error contact your distributor or DRG directly.

9 ASSAY CHARACTERISTICS

9.1 Assay Dynamic Range

The range of the assay is between 0.153 ng/mL - 81 ng/mL.

9.2 Specificity of Antibodies (Cross Reactivity)

The following substances were tested for cross reactivity of the assay:

Analyte	% Cross-Reactivity
Prohepcidin	< 0.001
Insulin	< 0.001
Hepcidin-22	24.2
Hepcidin-20	87.7

10 LIMITATIONS OF USE

Reliable and reproducible results will be obtained when the assay procedure is performed with a complete understanding of the package insert instruction and with adherence to good laboratory practice.

Any improper handling of samples or modification of this test might influence the results.

10.1 Interfering Substances

Hemoglobin (up to 4 mg/mL), Bilirubin (up to 0.5 mg/mL) and Triglyceride (up to 7.5 mg/mL) have no influence on the assay results.

10.2 Drug Interferences

Until today no substances (drugs) are known to us, which have an influence to the measurement of Hepcidin 25 in a sample.

10.3 High-Dose-Hook Effect

No hook effect was observed in this test.









Revised 30 Mar. 2015 rm (Vers. 1.1)

11 LEGAL ASPECTS

11.1 Reliability of Results

The test must be performed exactly as per the manufacturer's instructions for use. Moreover the user must strictly adhere to the rules of GLP (Good Laboratory Practice) or other applicable national standards and/or laws. This is especially relevant for the use of control reagents. It is important to always include, within the test procedure, a sufficient number of controls for validating accuracy and precision of the test.

The test results are valid only if all controls are within the specified ranges and if all other test parameters are also within the given assay specifications. In case of any doubt or concern please contact DRG.

11.2 Liability

Any modification of the test kit and/or exchange or mixture of any components of different lots from one test kit to another could negatively affect the intended results and validity of the overall test. Such modification and/or exchanges invalidate any claim for replacement.

Regardless, in the event of any claim, the manufacturer's liability is not to exceed the value of the test kit. Any damage caused to the test kit during transportation is not subject to the liability of the manufacturer.

12 REFERENCES

- Scamuffa N, et al. Regulation of prohepcidin processing and activity by the subtilisin-like proprotein convertases Furin, PC5, PACE4 and PC7. Gut. 2008; 57(11):1573-82.
- Kemna<u>EH</u>, <u>Tjalsma H</u>, <u>Podust VN</u>, <u>Swinkels DW</u>. Mass spectrometry-based hepcidin measurements in serum and urine: analytical aspects and clinical implications. <u>Clin. Chem.</u> 2007; 53(4):620-8.
- 3. Krause <u>A</u> et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. <u>FEBS Lett.</u> 2000; 480(2-3):147-50.
- 4. Kroot J et al. Hepcidin in Human Iron Disorders: Diagnostic Implications. Clin. Chem. 2011; 57:121650–1669.
- 5. Nemeth <u>E</u>, <u>Ganz T</u>. The role of hepcidin in iron metabolism. <u>Acta Haematol.</u> 2009; 122(2-3):78-86.
- 6. Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of Mammalian iron metabolism. Cell. 2010; 142:24 –38.
- Swinkels DW, Jorna AT, Raymakers RA. <u>Synopsis of the Dutch multidisciplinary guideline for the diagnosis and treatment of hereditary haemochromatosis</u>. Neth. J. Med. 2007; 65(11):452-5.
- 8. <u>Camaschella C</u>, <u>Silvestri L</u>. Molecular mechanisms regulating hepcidin revealed by hepcidin disorders. <u>Scientific World Journal</u>. 2011; 11:1357-66.





((

DRG[®] Hepcidin 25 (bioactive) HS ELISA (EIA-5782)



- Girelli D et al. <u>Reduced serum hepcidin levels in patients with chronic hepatitis C.</u> J. Hepatol. 2009; 51(5):845-52.
- Gardenghi S et al. Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by downregulation of hepcidin and up-regulation of ferroportin. Blood. 2007; 109:5027–35.
- 11. Uehata T et al. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study.

Nephrol Dial. Transplant. 2012; 27(3):1076-83.

 Peeling P, Dawson B, Goodman C, Landers G, Trinder D. Athletic induced iron deficiency: new insights into the role of inflammation, cytokines and hormones. Eur. J. Appl. Physiol. 2008; 103: 381–91.









CE

Revised 30 Mar. 2015 rm (Vers. 1.1)

Used Symbols

	1
Symbol	English
CE	European Conformity
Ĩ	Consult instructions for use
IVD	In vitro diagnostic device
RUO	For research use only
REF	Catalogue number
LOT	Lot. No. / Batch code
Σ	Contains sufficient for <n> tests/</n>
	Storage Temperature
2	Expiration Date
	Legal Manufacturer
Distributed by	Distributor
Content	Content
Volume/No.	Volume / No.
Microtiterwells	Microtiterwells
Antiserum	Antiserum
Enzyme Conjugate	Enzyme Conjugate
Enzyme Complex	Enzyme Complex
Substrate Solution	Substrate Solution
Stop Solution	Stop Solution
Zero Standard	Zero Standard
Standard	Standard
Control	Control
Assay Buffer	Assay Buffer
Wash Solution	Wash Solution
1N NaOH	1N NaOH
1 N HCl	1 N HCl
Sample Diluent	Sample Diluent
Conjugate Diluent	Conjugate Diluent

Rev. 2015/03-mh/vk_rm

